+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Survival following interstitial brachytherapy for recurrent malignant glioma



Survival following interstitial brachytherapy for recurrent malignant glioma



Journal of Neuro-Oncology 18(1): 33-39



The treatment of recurrent malignant glioma is difficult and at present largely disappointing. Furthermore the results of any treatment modality need to be interpreted with knowledge regarding patient selection and timing of treatment. The results of interstitial brachytherapy using iodine-125 in 23 patients are presented. There were no operative complications. Median survival time from tumour recurrence and implantation was 36 and 25 weeks respectively. Karnofsky Performance Status (KPS) was significantly associated with survival, though patient age, original tumour histology, prior chemotherapy, and time to recurrence were not. Treatment does confer modest survival benefit as compared to controls, but our results are not as impressive as others. Reasons for this finding are discussed.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047500656

Download citation: RISBibTeXText

PMID: 8057132


Related references

Interstitial Brachytherapy versus Cytoreductive Surgery in Recurrent Malignant Glioma. Stereotactic and Functional Neurosurgery 63(1-4): 241-245, 1995

Interstitial brachytherapy versus cytoreductive surgery in recurrent malignant glioma. Stereotactic and Functional Neurosurgery 63(1-4): 241-245, 1994

Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. Journal of Neurosurgery 67(6): 864-873, 1987

Stereotactic interstitial brachytherapy for malignant glioma. International Journal of Radiation Oncology*Biology*Physics 10(supp-S2): 201-202, 1984

Proliferative potential of malignant glioma cells before and after interstitial brachytherapy. Neurologia Medico-Chirurgica 39(5): 341-349, 1999

Radiation risks to personnel and public during the treatment of malignant glioma using interstitial brachytherapy. British Journal of Radiology 66(790): 915-917, 1993

Interstitial hyperthermia and brachytherapy for malignant glioma results of a phase i clinical trial. Neurology 41(3 SUPPL 1): 411, 1991

Iridium-192 brachytherapy in combination with interstitial microwave-induced hyperthermia for malignant glioma. Applied Neurophysiology 50(1-6): 287-291, 1987

Interstitial hyperthermia and iridium brachytherapy in treatment of malignant glioma. A phase I clinical trial. Journal of Neurosurgery 64(4): 581-587, 1986

CT guided interstitial HDR brachytherapy for recurrent malignant gliomas. International Journal of Radiation Oncology Biology Physics 51(3 Suppl. 1): 202, 2001

CT based interstitial HDR brachytherapy for the treatment of recurrent malignant gliomas. International Journal of Radiation Oncology*biology*physics 42(1-Supp-S1): 268-0, 1998

The gliasite radiation therapy system (RTS): a novel approach to brain brachytherapy for recurrent malignant glioma. International Journal of Radiation Oncology*biology*physics 51(3-Supp-S1): 203-0, 2001

The GliaSite radiation therapy system A novel approach to brain brachytherapy for recurrent malignant glioma. International Journal of Radiation Oncology Biology Physics 51(3 Suppl. 1): 203, 2001

CT guided interstitial high dose rate brachytherapy for recurrent malignant gliomas. British Journal of Radiology 72(860): 805-808, 2000

Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. Journal of Neuro-Oncology 27(2): 157-162, 1996